Abstract:Background Phosphoinositide-3-kinase Delta (PI3K delta) plays a key role in B-cell signal transduction and inhibition of PI3K delta is confirmed to have clinical benefit in certain types of activation of B-cell malignancies. Virtual screening techniques have been used to discover new molecules for developing novel PI3K delta inhibitors with little side effects. Method: Computer aided drug design method were used to rapidly screen optimal PI3K delta inhibitors from the Asinex database. Virtual screening based molecular docking was performed to find novel and potential lead compound targeting PI3K delta, at first. Subsequently, drug likeness studies were carried out on the retrieved hits to evaluate and analyze their drug like properties such as absorption, distribution, metabolism, excretion, and toxicity (ADMET) for toxicity prediction. Three least toxic compounds were selected for the molecular dynamics (MD) simulations for 30 ns in order to validate its stability inside the active site of PI3K delta receptor. Results: Based on the present in silico analysis, two molecules have been identified which occupied the same binding pocket confirming the selection of active site. ASN 16296138 (Glide score: - 12.175 kcal/mol, cdocker binding energy: - 42.975 kcal/mol and Delta G(bind) value: - 90.457 kcal/mol) and HAS 00227397 (Glide score: - 10.988 kcal/mol, cdocker binding energy: - 39.3376 kcal/mol and Delta G(bind) value: - 81.953 kcal/mol) showed docking affinities comparatively much stronger than those of already reported known inhibitors against PI3K delta. These two ligand's behaviors also showed consistency during the simulation of protein-ligand complexes for 30000 ps respectively, which is indicative of its stability in the receptor pocket. Conclusion: Compound ASN 16296138 and BAS 00227397 are potential candidates for experimental validation of biological activity against PI3K delta in future drug discovery studies. This study smoothes the path for the development of novel leads with improved binding properties, high drug likeness, and low toxicity to humans for the treatment of cancer.

Identification of potent CypD inhibitors via pharmacophore based virtual screening, docking and molecular dynamics simulation

Discovering Novel Chemical Inhibitors of Human Cyclophilin A: Virtual Screening, Synthesis, and Bioassay

Refinement and 3D‐QSAR Studies of Inhibitors of Cyclophilin A Containing Amide Linker

Discovering Potent Small Molecule Inhibitors of Cyclophilin A Using De Novo Drug Design Approach

Identification of Phosphoinositide-3 Kinases Delta and Gamma Dual Inhibitors Based on the P110δ/γ Crystal Structure

Identification of Novel Tyrosinase Inhibitors with Nanomolar Potency Using Virtual Screening Approaches

Identification of Novel PPARα/γ Dual Agonists by Pharmacophore Screening, Docking Analysis, ADMET Prediction and Molecular Dynamics Simulations.

Discovery of novel cholesteryl ester transfer protein (CETP) inhibitors by a multi-stage virtual screening

Computational Study On Natural Compounds Inhibitor Of C-Myc

Identification of novel natural inhibitors of Opisthorchis felineus cytochrome P450 using structure-based screening and molecular dynamic simulation

One Novel Quinoxaline Derivative As a Potent Human Cyclophilin A Inhibitor Shows Highly Inhibitory Activity Against Mouse Spleen Cell Proliferation

Identification of Novel Inhibitors of P-Hydroxyphenylpyruvate Dioxygenase Using Receptor-Based Virtual Screening

Identification of Diverse Dipeptidyl Peptidase IV Inhibitors Via Structure-Based Virtual Screening

Discovery of non-peptidic small molecule inhibitors of cyclophilin D as neuroprotective agents in Aβ-induced mitochondrial dysfunction

Identification of Novel PI3Kδ Inhibitors by Docking, ADMET Prediction and Molecular Dynamics Simulations.

Identification of Novel Src Inhibitors: Pharmacophore-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations

Combining Virtual Screening and in Vitro Evaluation for the Discovery of Potential CYP11B2 Inhibitors.

Computer-Aided Identification of Potential Tyk2 Inhibitors from Drug Database

Identification of dipeptidyl peptidase IV inhibitors: virtual screening, synthesis and biological evaluation.

Computational Study on New Natural Compound Inhibitors of Pyruvate Dehydrogenase Kinases

Exploring New Potential Pkcθ Inhibitors Using Pharmacophore Modeling, Molecular Docking Analysis, and Molecular Dynamics Simulations